The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031
- PMID: 26902923
- DOI: 10.1016/j.jid.2016.01.035
The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031
Abstract
New melanoma therapies are being developed rapidly, complementing prevention and detection strategies for disease control. Estimating the future burden of melanoma is necessary for deciding how best to deploy limited resources to achieve effective melanoma control. Using three decades of cancer registry data (1982-2011) from six populations with moderate to high melanoma incidence (US whites and the populations of the United Kingdom, Sweden, Norway, Australia, New Zealand), we applied age-period-cohort models to describe current trends and project future incidence rates and numbers of melanomas out to 2031. Between 1982 and 2011, melanoma rates in US whites, and the populations of the United Kingdom, Sweden, and Norway increased at more than 3% annually and are projected to continue rising until at least 2022. Melanoma incidence in Australia has been declining since 2005 (-0.7% per year), and melanoma incidence in New Zealand is increasing but is projected to decline soon. The numbers of new melanoma cases will rise in all six populations because of aging populations and high age-specific rates in the elderly. In US whites, annual new cases will rise from around 70,000 in 2007-2011 to 116,000 in 2026-2031, with 79% of the increase attributable to rising age-specific rates and 21% to population growth and aging. The continued increases in case numbers in all six populations through 2031 will increase the challenges of melanoma control.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Comment in
-
The Relentless Rise in the Incidence of Melanoma in Susceptible Australians.J Invest Dermatol. 2016 Sep;136(9):1912-1913. doi: 10.1016/j.jid.2016.04.028. Epub 2016 May 26. J Invest Dermatol. 2016. PMID: 27236104 No abstract available.
-
Response to Czarnecki.J Invest Dermatol. 2016 Sep;136(9):1913-1914. doi: 10.1016/j.jid.2016.05.096. Epub 2016 May 26. J Invest Dermatol. 2016. PMID: 27236106 No abstract available.
Similar articles
-
Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002.Cancer Causes Control. 2006 Feb;17(1):21-7. doi: 10.1007/s10552-005-3637-4. Cancer Causes Control. 2006. PMID: 16411049
-
International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?Int J Cancer. 2013 Jan 15;132(2):385-400. doi: 10.1002/ijc.27616. Epub 2012 May 21. Int J Cancer. 2013. PMID: 22532371
-
Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010.JAMA Dermatol. 2014 May;150(5):526-34. doi: 10.1001/jamadermatol.2013.9852. JAMA Dermatol. 2014. PMID: 25093216
-
Cutaneous melanoma.Cancer Surv. 1994;19-20:219-40. Cancer Surv. 1994. PMID: 7534627 Review.
-
Update on the current state of melanoma incidence.Dermatol Clin. 2012 Jul;30(3):355-61. doi: 10.1016/j.det.2012.04.001. Epub 2012 Jun 8. Dermatol Clin. 2012. PMID: 22800543 Review.
Cited by
-
Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis.Int J Mol Sci. 2023 Nov 14;24(22):16281. doi: 10.3390/ijms242216281. Int J Mol Sci. 2023. PMID: 38003476 Free PMC article. Review.
-
Manganese-Doped Calcium Silicate Nanowire Composite Hydrogels for Melanoma Treatment and Wound Healing.Research (Wash D C). 2021 May 7;2021:9780943. doi: 10.34133/2021/9780943. eCollection 2021. Research (Wash D C). 2021. PMID: 34041493 Free PMC article.
-
Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib.Int J Mol Sci. 2021 Apr 22;22(9):4387. doi: 10.3390/ijms22094387. Int J Mol Sci. 2021. PMID: 33922284 Free PMC article.
-
Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines.Int J Mol Sci. 2024 Jan 28;25(3):1615. doi: 10.3390/ijms25031615. Int J Mol Sci. 2024. PMID: 38338893 Free PMC article.
-
MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8.Sci Rep. 2021 Mar 11;11(1):5660. doi: 10.1038/s41598-021-85097-6. Sci Rep. 2021. Retraction in: Sci Rep. 2022 Sep 27;12(1):16103. doi: 10.1038/s41598-022-21189-1 PMID: 33707587 Free PMC article. Retracted.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical